APA (7th ed.) Citation

AB, L., SL, P., TJC, W., K, A., HK, G., M, P., . . . MP, M. (2023). Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. Neuro-oncology, 25(2), 339. https://doi.org/10.1093/neuonc/noac173

Chicago Style (17th ed.) Citation

AB, Lassman, et al. "Depatuxizumab Mafodotin in EGFR-amplified Newly Diagnosed Glioblastoma: A Phase III Randomized Clinical Trial." Neuro-oncology 25, no. 2 (2023): 339. https://doi.org/10.1093/neuonc/noac173.

MLA (9th ed.) Citation

AB, Lassman, et al. "Depatuxizumab Mafodotin in EGFR-amplified Newly Diagnosed Glioblastoma: A Phase III Randomized Clinical Trial." Neuro-oncology, vol. 25, no. 2, 2023, p. 339, https://doi.org/10.1093/neuonc/noac173.